Abstract Objective: Tamoxifen was not used earlier in clinical practice to decrease the urethral re-stricture rate after visual internal urethrotomy (VIU). In this study, we are the first to report the use of Tamoxifen as an adjuvant therapy to decrease the re-fibrosis and stricture recurrence post-VIU. Patients and Methods: Between 2015 and 2017, 60 patients underwent VIU for post-traumatic bulbar urethral stricture ≤1 cm. They were randomly divided into 2 groups (30 patients each). The Tamoxifen group cases received Tamoxifen 10 mg twice daily for 6 months post-VIU. The control group did not receive any medications. All patients were evaluated using the IPSS score, uroflowmetry, and perineal ultrasonography preoperatively at 3 and 6 months. Results: At presentation, there was no significant difference between patients of both groups in terms of IPSS score, Qmax, stricture width, and length. At 6 months follow-up, the mean IPSS score for the Tamoxifen group was 12.3 (8–19) in comparison with 20 (12–26) in the control group (p < 0.001). The Tamoxifen group had mean Qmax 11.1 mL/s (9–14), while those of the control group had mean Qmax 8.2 mL/s (6–10; p < 0.001). Using perineal ultrasound, only stricture width showed to be significantly smaller in the Tamoxifen group (p = 0.001). Conclusion: Tamoxifen seemed to be effective in reducing the recurrence of urethral stricture post-VIU. There was a significant improvement of the clinical outcome regarding Qmax and IPSS score after Tamoxifen adjuvant therapy.

Keywords:
Urethral stricture, Tamoxifen, Internal urethrotomy, Ultrasonography
1.
Albers P, Fichtner J, Bruhl P, et al: Long-term results of internal urethrotomy. J Urol 1996; 156: 611–1614.
2.
Pansadoro V, Emiliozzi P: Internal urethrotomy in the management of anterior urethral strictures: long-term followup. J Urol 1996; 156: 73–75.
3.
Santucci R, Eisenberg L: Urethrotomy has a much lower success rate than previously reported. J Urol 2010; 183: 1859–1862.
4.
Ralph DJ, Brooks MD, Bottazzo GF, et al: The treatment of Peyronie’s disease with tamoxifen. Br J Urol 1992; 70: 648–651.
5.
van Bommel EF, Hendriksz TR, Huiskes AW, et al: Brief communication: tamoxifen therapy for nonmalignant retroperitoneal fibrosis. Ann Intern Med 2006; 144: 101–106.
6.
Jordan VC: Tamoxifen: a most unlikely pioneering medicine. Nat Rev Drug Discov 2003; 2: 205–213.
7.
Jackson MJ, Veeratterapillay R, Harding CK, et al: Intermittent self-dilatation for urethral stricture disease in males. Cochrane Database Syst Rev 2014; 12:CD010258.
8.
Kunz I, Musch M, Vogel A, et al: Experience with one-stage repair of urethral strictures using the augmented anastomotic repair technique. Urol Int 2018; 100: 386–396.
9.
Verla W, Waterloos M, Lumen N: Urethroplasty and quality of life: psychometric vof a dutch version of the urethral stricture surgery patient reported outcome measures. Urol Int 2017; 99: 460–466.
10.
Mundy AR: Management of urethral strictures. Postgrad Med J 2006; 82: 489–493.
11.
Dubey D: The current role of direct vision internal urethrotomy and self-catheterization for anterior urethral strictures. Indian J Urol 2011; 27: 392–396.
12.
Torres Castellanos L, Moreno Bencardino MC, Bravo-Balado A, et al: Evaluation of the efficacy and safety of laser versus cold knife urethrotomy in the management of patients with urethral strictures: a systematic review and meta-analysis of randomized clinical trials. Urol Int 2017; 99: 453–459.
13.
Moradi M, Derakhshandeh K, Karimian B, et al: Safety and efficacy of Intraurethral Mitomycin C Hydrogel for prevention of post-traumatic anterior urethral stricture recurrence after internal urethrotomy. J Inj Violence Res 2016; 8: 75–79.
14.
Khan S, Khan RA, Ullah A, et al: Role of clean intermittent self catheterisation (CISC) in the prevention of recurrent urethral strictures after internal optical urethrotomy. J Ayub Med Coll Abbottabad 2011; 23: 22–25.
15.
Kamp S, Knoll T, Osman MM, et al: Low-power holmium:YAG laser urethrotomy for treatment of urethral strictures: functional outcome and quality of life. J Endourol 2006; 20: 38–41.
16.
Ali L, Shahzad M, Orakzai N, et al: Efficacy of mitomycin C in reducing recurrence of anterior urethral stricture after internal optical urethrotomy. Korean J Urol 2015; 56: 650–655.
17.
Kumar S, Kapoor A, Ganesamoni R, et al: Efficacy of holmium laser urethrotomy in combination with intralesional triamcinolone in the treatment of anterior urethral stricture. Korean J Urol 2012; 53: 614–618.
18.
Mazdak H, Meshki I, Ghassami F: Effect of mitomycin C on anterior urethral stricture recurrence after internal urethrotomy. Eur Urol 2007; 51: 1089–1092; discussion 92.
19.
Chung JH, Kang DH, Choi HY, et al: The effects of hyaluronic acid and carboxymethylcellulose in preventing recurrence of urethral stricture after endoscopic internal urethrotomy: a multicenter, randomized controlled, single-blinded study. J Endourol 2013; 27: 756–762.
20.
Carthy JM, Sundqvist A, Heldin A, et al: Tamoxifen Inhibits TGF-β-mediated activation of myofibroblasts by blocking non-Smad signaling through ERK1/2. J Cell Physiol 2015; 230: 3084–3092.
21.
Brandt AS, Kamper L, Kukuk S, et al: Tamoxifen monotherapy in the treatment of retroperitoneal fibrosis. Urol Int 2014; 93: 320–325.
22.
Worst TS, Daskalova K, Steidler A, et al: Impact of altered WNT2B expression on bladder wall fibroblasts: implications for apoptosis regulation in the stroma of the lower urinary tract. Urol Int 2017; 99: 476–483.
23.
Gupta N, Dubey D, Mandhani A, et al: Urethral stricture assessment: a prospective study evaluating urethral ultrasonography and conventional radiological studies. BJU Int 2006; 98: 149–153.
24.
Vaglio A, Palmisano A, Alberici F, et al: Prednisone versus tamoxifen in patients with idiopathic retroperitoneal fibrosis: an open-label randomised controlled trial. Lancet 2011; 378: 338–346.
25.
Decensi A, Maisonneuve P, Rotmensz N, et al: Effect of tamoxifen on venous thromboembolic events in a breast cancer prevention trial. Circulation 2005; 111: 650–656.
26.
Morey AF, McAninch JW: Ultrasound evaluation of the male urethra for assessment of urethral stricture. J Clin Ultrasound 1996; 24: 473–479.
27.
Yildirim ME, Kaynar M, Ozyuvali E, et al: The effectiveness of local steroid injection after internal urethrotomy to avoid recurrence. Arch Ital Urol Androl 2016; 87: 295–298.
28.
Hosseini J, Kaviani A, Golshan AR: Clean intermittent catheterization with triamcinolone ointment following internal urethrotomy. Urol J 2008; 5: 265–268.
29.
Mazdak H, Izadpanahi MH, Ghalamkari A, et al: Internal urethrotomy and intraurethral submucosal injection of triamcinolone in short bulbar urethral strictures. Int Urol Nephrol 2010; 42: 565–568.
30.
Gucuk A, Tuygun C, Burgu B, et al: The short-term efficacy of dilatation therapy combined with steroid after internal urethrotomy in the management of urethral stenoses. J Endourol 2010; 24: 1017–1021.
31.
Tavakkoli Tabassi K, Yarmohamadi A, Mohammadi S: Triamcinolone injection following internal urethrotomy for treatment of urethral stricture. Urol J 2011; 8: 132–136.
32.
Olschewski T, Kropfl D, Seegenschmiedt MH: Endourethral brachytherapy for prevention of recurrent urethral stricture following internal urethrotomy-first clinical experiences and results. Int J Radiat Oncol Biol Phys 2003; 57: 1400–1404.
33.
Kropfl D, Olschewski T, Seegenschmiedt MH: [Endourethral brachytherapy for the prevention of recurrent strictures following internal urethrotomy]. Urologe A 2004; 43: 1254–1261.
34.
Sun YH, Xu CL, Gao X, et al: Intraurethral brachytherapy for prevention of recurrent urethral stricture after internal urethrotomy or transurethral resection of scar. J Endourol 2001; 15: 859–861.
35.
Kjaergaard B, Walter S, Bartholin J, et al: Prevention of urethral stricture recurrence using clean intermittent self-catheterization. Br J Urol 1994; 73: 692–695.
36.
Bodker A, Ostri P, Rye-Andersen J, et al: Treatment of recurrent urethral stricture by internal urethrotomy and intermittent self-catheterization: a controlled study of a new therapy. J Urol 1992; 148 (2 pt 1): 308–310.
37.
Roosen JU: Self-catheterization after urethrotomy. Prevention of urethral stricture recurrence using clean intermittent self-catheterization. Urol Int 1993; 50: 90–92.
38.
Tunc M, Tefekli A, Kadioglu A, et al: A prospective, randomized protocol to examine the efficacy of postinternal urethrotomy dilations for recurrent bulbomembranous urethral strictures. Urology 2002; 60: 239–244.
39.
Lin YH, Huang WJ, Chen KK: Using stainless steel chopstick for self-performing urethral sounding in preventing recurrence of anterior urethral stricture. J Chin Med Assoc 2006; 69: 189–192.
40.
Rijal A, Little B, McPhee S, et al: Intermittent self dilatation-still a viable option for treatment of urethral stricture disease. Nepal Med Coll J 2008; 10: 155–159.
41.
Lauritzen M, Greis G, Sandberg A, et al: Intermittent self-dilatation after internal urethrotomy for primary urethral strictures: a case-control study. Scand J Urol Nephrol 2009; 43: 220–225.
42.
Greenwell TJ, Castle C, Nicol DL: Clean intermittent self-catheterization does not appear to be effective in the prevention of urethral stricture recurrence. Scand J Urol 2016; 50: 71–73.
43.
Mkony CA: Hydraulic urethral dilatation after optical internal urethrotomy: preliminary report. East Afr Med J 1999; 76: 680–682.
44.
Kumar S, Garg N, Singh SK, et al: Efficacy of optical internal urethrotomy and intralesional iof Vatsala-Santosh PGI tri-inject (triamcinolone, mitomycin C, and hyaluronidase) in the treatment of anterior urethral stricture. Adv Urol 2014; 2014: 192710.
45.
Shirazi M, Khezri A, Samani SM, et al: Effect of intraurethral captopril gel on the recurrence of urethral stricture after direct vision internal urethrotomy: Phase II clinical trial. Int J Urol 2007; 14: 203–208.
46.
Kim HM, Kang DI, Shim BS, et al: Early experience with hyaluronic Acid instillation to assist with visual internal urethrotomy for urethral stricture. Korean J Urol 2010; 51: 853–857.
© 2018 S. Karger AG, Basel
2018
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.